Join to view full profile
3400 Spruce StPhiladelphia, PA 19104
Phone+1 215-360-0735
Dr. O'Hara is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2012 - 2015
UPMC Medical EducationResidency, Internal Medicine, 2008 - 2012
Stony Brook University Health Sciences Center School of MedicineClass of 2008
Certifications & Licensure
PA State Medical License 2008 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2016-2017
Clinical Trials
- Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Start of enrollment: 2016 Jan 26
- A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
- A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies Start of enrollment: 2019 Nov 06
Publications & Presentations
PubMed
- 272 citationsAn NK-like CAR T cell transition in CAR T cell dysfunction.Charly R. Good, M. Angela Aznar, Shunichiro Kuramitsu, Parisa Samareh, Sangya Agarwal
Cell. 2021-12-02 - 3 citationsTHSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma.Phyllis A. Gimotty, Jacob Till, Shirsa Udgata, Naomi Takenaka, Stephanie S. Yee
Oncotarget. 2021-10-26 - 4 citationsConcurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer.William Tristram Arscott, Kevin T. Nead, Adham S. Bear, Sriram Venigalla, Jacob E. Shabason
American Journal of Clinical Oncology. 2021-09-01
Press Mentions
Verismo Therapeutics Announces the Activation of Its STAR-101 Clinical Trial at the University of PennsylvaniaMay 2nd, 2023- New Approach for Cell Therapy Shows Potential Against Solid Tumors with KRAS MutationsJuly 27th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
